Skip to main content

Biogen Inc(BIIB-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low181.24
Day High186.25
Open:186.25
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

TOP STORIES: Biogen Inc

Select a category then submit the form to load news
Zacks Investment Research
Will AbbVie's Neuroscience Segment Continue to Aid Top Line in 2026?
Will AbbVie's Neuroscience Segment Continue to Aid Top Line in 2026?
GlobeNewswire
Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences
GlobeNewswire
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
Tipranks
Biogen Deepens Its ALS Footprint With Long-Term Qalsody Safety Registry
Tipranks
Biogen (BIIB) Receives a Buy from RBC Capital
Zacks Investment Research
Ionis Q4 Earnings & Sales Beat, Stock Down on Soft 2026 Outlook
Ionis Q4 Earnings & Sales Beat, Stock Down on Soft 2026 Outlook
Tipranks
Biogen’s BIIB091 MS Trial Reaches Completion, Setting Up a Key Pipeline Catalyst
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Biogen (BIIB), Guardant Health (GH) and PTC Therapeutics (PTCT)
StockStory
3 Value Stocks Walking a Fine Line
PANL
StockStory
The 5 Most Interesting Analyst Questions From Biogen’s Q4 Earnings Call
BIIB
StockStory
1 Unpopular Stock That Deserves a Second Chance and 2 We Find Risky
BIIB
Tipranks
Biogen Announces Board Chair Caroline Dorsa to Step Down
Tipranks
Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Biogen (BIIB) and Quest Diagnostics (DGX)
GlobeNewswire
Biogen Announces Board Chair Transition
Tipranks
Analysts Offer Insights on Healthcare Companies: Centene (CNC) and Biogen (BIIB)
Tipranks
Biogen Earnings Call: Solid 2025, Cautious 2026 Outlook
Tipranks
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Biohaven Ltd. (BHVN) and Adaptive Biotechnologies (ADPT)
Tipranks
Analysts Offer Insights on Healthcare Companies: McKesson (MCK) and Biogen (BIIB)
Tipranks
Wedbush Keeps Their Hold Rating on Biogen (BIIB)
StockStory
BIIB Q4 Deep Dive: Pipeline Advances and New Product Launches Offset Legacy Headwinds
BIIB
Motley Fool
Why Biogen Stock Surged Almost 9% Higher on Friday
Motley Fool
Biogen (BIIB) Q4 2025 Earnings Call Transcript
StockStory
Biogen’s (NASDAQ:BIIB) Q4 CY2025: Strong Sales
BIIB
StockStory
Biogen (BIIB) Reports Q4: Everything You Need To Know Ahead Of Earnings
BIIB
Tipranks
Analysts Offer Insights on Healthcare Companies: Tenet Healthcare (THC), Revvity (RVTY) and Biogen (BIIB)
Tipranks
Biogen (BIIB) Receives a Buy from RBC Capital
GlobeNewswire
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
Tipranks
Bank of America Securities Reaffirms Their Hold Rating on Biogen (BIIB)
StockStory
1 Cash-Producing Stock to Keep an Eye On and 2 We Find Risky
ULTA
Baystreet
Jobs Reports Rate Full Attention
Tipranks
Jefferies Remains a Buy on Biogen (BIIB)
GlobeNewswire
Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options

Profile

Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.